China’s National Medical Products Administration approved Suzhou Alphamab’s HER2 bispecific antibody anbenitamab (KN-026) via priority review for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after at least one trastuzumab-containing regimen. The decision adds a new option in a heavily biomarker-driven oncology space. Separately, Everest Medicines accelerated its Asia-Pacific late-stage buildout with a string of transactions, including a Travere civorebrutinib deal valued above $1.14 billion and additional deals over six days to expand pipeline breadth and geographic reach. The combined signal is that regulatory clearance and licensing activity remain tightly coupled in the region: approvals help validate claims for partners and monetize pipelines, while large portfolio transactions are used to diversify late-stage risk across multiple indications.